SHARx Challenges CFOs to View Pharmacy Costs as Workforce Strategy

Bureau of Labor Statistics data confirms that private sector health benefit costs rose 6% over the past year, doubling the 3.1% growth rate for wages. When pharmacy spending exceeds forecasts, companies often resort to cost-shifting—increasing deductibles or copays—rather than addressing the underlying waste. Pruitt warns that this approach merely masks the problem while fueling employee dissatisfaction and administrative friction.

Strategic Alignment of HR and Finance

CFOs should view pharmacy inflation as an opportunity cost. Every dollar lost to inefficient drug sourcing is capital diverted from merit increases, retirement contributions, or new hires. Pruitt advocates for a joint ownership model where HR and finance leaders analyze specialty medication exposure and prescription abandonment rates alongside broader recruitment goals. Success should be measured by predictability and access rather than simply chasing the lowest projected contract price. By treating the pharmacy benefit as a core business lever, organizations can protect their workforce investments while maintaining sustainable long-term budgets.